U-Neuron Biomedical (ROCO:6973) Peter Lynch Fair Value: N/A (As of Aug. 07, 2026)

U-Neuron Biomedical  (ROCO:6973) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

U-Neuron Biomedical's Price to Peter Lynch Fair Value Ratio for today is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

U-Neuron Biomedical Peter Lynch Fair Value Related Terms

The historical data trend for U-Neuron Biomedical's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

U-Neuron Biomedical Peter Lynch Fair Value Chart

U-Neuron Biomedical Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Peter Lynch Fair Value	Get a 7-Day Free Trial					0.00	0.00	0.00	0.00	0.00

ROCO:6973 vs VRTX, REGN, RVMD: Peter Lynch Fair Value Comparison

For the Biotechnology subindustry, U-Neuron Biomedical's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

U-Neuron Biomedical Price-to-Peter-Lynch-Fair-Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, U-Neuron Biomedical's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where U-Neuron Biomedical's Price-to-Peter-Lynch-Fair-Value falls into.

U-Neuron Biomedical Peter Lynch Fair Value Calculation

U-Neuron Biomedical's Peter Lynch Fair Value for today is calculated as

For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. U-Neuron Biomedical's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.42.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.

U-Neuron Biomedical Business Description